The germline BRCA1/2 pathogenic variants are widely reported among families with a strong history of breast/ovarian cancer,10, 39, 40 cohort of early‐onset BC patients,41 triple‐negative BC patients,42 pancreatic cancer patients,9 and among patients with prostate cancer.8, 43. This evidence concerns the gene BRCA1 and ovarian cancer.